What did we learn from the North American Cystic Fibrosis Conference?
Bilton
Diana
D
Department of Respiratory Medicine, Royal Brompton Hospital Sydney Street, London SW3 6NP, UK. d.bilton@rbht.nhs.uk
D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001398:Aztreonam / Q000627:therapeutic use*; D018118:Chloride Channels / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000502:physiology; D004234:Diuretics, Osmotic / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D017136:Ion Transport / Q000187:drug effects / Q000502:physiology; D008353:Mannitol / Q000627:therapeutic use; D011787:Quality of Health Care; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use; D014481:United States
D000900:Anti-Bacterial Agents; D018118:Chloride Channels; D004234:Diuretics, Osmotic; D012462:Saline Solution, Hypertonic; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D008353:Mannitol; D000583:Amikacin; D001398:Aztreonam